Clinical trials
Completed Observational Epilepsy trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
250 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 3 |
| 2002 | 6 |
| 2003 | 6 |
| 2004 | 3 |
| 2005 | 7 |
| 2006 | 8 |
| 2007 | 9 |
| 2008 | 9 |
| 2009 | 7 |
| 2010 | 18 |
| 2011 | 21 |
| 2012 | 13 |
| 2013 | 12 |
| 2014 | 7 |
| 2015 | 17 |
| 2016 | 10 |
| 2017 | 10 |
| 2018 | 13 |
| 2019 | 16 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 10 |
| 2023 | 10 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 250 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 20 |
| GlaxoSmithKline | 14 |
| UCB Pharma | 8 |
| Cyberonics, Inc. | 7 |
| Beth Israel Deaconess Medical Center | 4 |
| Centre Hospitalier Universitaire, Amiens | 4 |
| MedtronicNeuro | 4 |
| Northwell Health | 4 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 4 |
| Stanford University | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Epilepsy | 250 |
| Seizures | 56 |
| Epilepsies, Partial | 14 |
| Neoplasms | 7 |
| Epilepsy, Temporal Lobe | 6 |
| Migraine Disorders | 6 |
| Bipolar Disorder | 5 |
| Diabetes Mellitus | 5 |
| Inflammation | 5 |
| Stroke | 5 |
Trials
Showing 1 to 25 of 250. Each trial links to its page on Pharma Observatory.
150 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.